Clinical analysis of micafungin in prevention of fungal infection in neutropenic stage in patients with allogeneic hematopoietic stem cell transplantation
-
摘要:目的 探讨米卡芬净预防异基因造血干细胞移植(allo-HSCT)后中性粒细胞减少期真菌感染的临床疗效和安全性。方法 收集116例allo-HSCT患者的资料, 23例患者移植前有肺部真菌感染史，所有患者从预处理开始使用米卡芬净50 mg/d至中性粒细胞减少恢复。结果 6例患者临床诊断为肺部真菌感染，在米卡芬净使用过程中未观察到严重不良反应发生，也未因此而调整环孢素A浓度，至随访结束时, 83例患者存活。结论 米卡芬净预防allo-HSCT后中性粒细胞减少期真菌感染是安全、有效的，不影响环孢素A的血药浓度。
-
关键词:
- 米卡芬净 /
- 中性粒细胞减少 /
- 真菌感染 /
- 异基因造血干细胞移植
Abstract:Objective To explore the efficiency and safety of micafungin in preventing fungal infection in neutropenic stage in patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT).Methods The clinical data of 116 patients with allo-HSCT were collected, among whom 23 patients had a history of pulmonary fungal infection before transplantation. All patients were treated with micafungin for 50 mg daily from the beginning of pretreatment to recovery of neutropenia.Results Six patients were clinically diagnosed as pulmonary fungal infections. No serious adverse reactions were observed during the clinical observation, and concentration of cyclosporin A was not adjusted. By the end of follow-up, 83 patients survived.Conclusion Micafungin is safe and effective in preventing fungal infection in neutropenic stage after allo-HSCT without affecting the concentration of cyclosporine A in blood. -
-
[1] Busca A, Pagano L. Antifungal therapy in hematopoietic stem cell transplant recipients[J]. Mediterr J Hematol Infect Dis, 2016, 8(1): e2016039. http://www.ncbi.nlm.nih.gov/pubmed/27648202
[2] 中国侵袭性真菌感染工作组. 血液病/恶性肿瘤患者侵袭性真菌病的诊断标准与治疗原则(第五次修订版)[J]. 2017, 56(6): 453-459. [3] Wasmann R E, Muilwijk E W, Burger D M, et al. Clinical pharmacokinetics and pharmacodynamics of micafungin[J]. Clin Pharmacokinet, 2018, 57(3): 267-286. doi: 10.1007/s40262-017-0578-5
[4] Schonfeld W, Wang Cheng J, Tong K B, et al. Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation[J]. Clin Ther, 2008, 30(5): 964-973. doi: 10.1016/j.clinthera.2008.04.020
[5] Huang X J, Chen H, Han M Z, et al. Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant[J]. Biol Blood Marrow Transplant, 2012, 18(10): 1509-1516. http://www.ncbi.nlm.nih.gov/pubmed/22469884
[6] Langebrake C, Rohde H, Lellek H, et al. Micafungin as antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: results of different dosage levels in clinical practice[J]. Clin Transplant, 2014, 28(3): 286-291. doi: 10.1111/ctr.12310
[7] De Pauw B, Walsh T J, Donnelly J P, et al. Revised definitions of invasive fungal disease from the European organization for research and treatment of Cancer/Invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) consensus group[J]. Clin Infect Dis, 2008, 46(12): 1813-1821. doi: 10.1086/588660
[8] 黄晓兵, 王春森, 张晋林, 等. 米卡芬净在造血干细胞移植二级预防中的临床应用分析[J]. 华西医学, 2011, 26(12): 1783-1786. https://www.cnki.com.cn/Article/CJFDTOTAL-HXYX201112007.htm [9] 郭智, 陈惠仁, 杨凯, 等. 单倍型异基因造血干细胞移植后患者肺部真菌感染的临床研究[J]. 中华医院感染学杂志, 2015, 25(13): 2999-3001. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHYY201513047.htm [10] El-Cheikh J, Crocchiolo R, Vai A, et al. Comparison of three distinct prophylactic agents against invasive fungal infections in patients undergoing haplo-identical hematopoietic stem cell transplantation and post-transplant cyclophosphamide[J]. Mediterr J Hematol Infect Dis, 2015, 7(1): e2015048. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560261/
[11] 骆蓉, 王泽波, 徐世侠, 等. 造血干细胞移植中应用米卡芬净和伏立康唑预防霉菌感染的meta-分析[J]. 中国医师杂志, 2016, 18(4): 565-570. [12] 章忠明, 李桥川, 刘练金, 等. 米卡芬净与伊曲康唑预防造血干细胞移植患者早期真菌感染的效果及安全性比较[J]. 广西医学, 2017, 39(11): 1658-1660. https://www.cnki.com.cn/Article/CJFDTOTAL-GYYX201711013.htm -
期刊类型引用(15)
1. 李艳，何俊华. 人性化护理管理对精神分裂症恢复期患者生活质量的影响. 兵团医学. 2023(03): 79-80 . 
百度学术
2. 周建清. 智能电针仪结合广播体操对精神分裂症患者临床症状及睡眠质量的影响. 医疗装备. 2022(16): 180-182 . 百度学术
3. 吕秋菊，黄菊香，戴霞，周艳. 个性化心理护理干预对精神分裂症患者的效果研究. 心理月刊. 2022(21): 67-69 . 百度学术
4. 王成芳. 预见性风险评估在精神科安全护理中的干预效果分析. 中外医疗. 2020(11): 144-146 . 百度学术
5. 孙慧. 预见性护理对精神分裂症患者危险行为的预防及改善. 实用临床护理学电子杂志. 2020(23): 78-79 . 百度学术
6. 赵丽敏. 人性化护理管理对恢复期精神分裂症患者的影响研究. 中国医药指南. 2020(18): 207-208 . 百度学术
7. 黄凌. 个性化干预方案对精神分裂症患者社会功能康复的影响. 中国医药指南. 2020(25): 22-23+26 . 百度学术
8. 谢芳，李惠颖. 个性化护理干预对精神分裂症患者生活质量和社会功能恢复的影响. 中外医学研究. 2019(06): 102-104 . 百度学术
9. 秦颖. 整体护理服务在偏执型精神分裂症患者社会功能中的应用价值分析. 中外医疗. 2019(05): 163-165 . 百度学术
10. 刘建平. 精神分裂症护理对患者康复及生活质量的影响观察. 世界最新医学信息文摘. 2019(89): 345+347 . 百度学术
11. 熊令辉，陶慧琪. 个性化护理干预对精神分裂症患者社会功能恢复的影响. 齐鲁护理杂志. 2018(15): 71-73 . 百度学术
12. 李玲，李小妹. 精神分裂症患者接受心理护理干预对抑郁症状及睡眠质量的改善效果. 世界睡眠医学杂志. 2018(06): 737-739 . 百度学术
13. 王军华，李玲. 综合护理干预对首发男性精神分裂症患者认知功能的影响. 实用临床医药杂志. 2018(12): 37-40 . 本站查看
14. 张蕾. 综合护理干预应用于紧张型精神分裂症木僵状态患者的护理效果. 继续医学教育. 2018(11): 132-134 . 百度学术
15. 曾玉琼，陈健蒲，陈秋丽. 个性化护理在重症颅脑损伤患者护理中的应用价值. 中国当代医药. 2018(35): 197-199 . 百度学术
其他类型引用(1)
计量
- 文章访问数: 232
- HTML全文浏览量: 144
- PDF下载量: 7
- 被引次数: 16
下载:
苏公网安备 32100302010246号
